Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267746 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 893
- Enrollment target
NCT02267746: Completed Phase 3 study, sponsored by Actavis.
NCT02267746 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 893 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267746, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 893 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
Primary Outcome
For the purposes of study treatment and evaluation, these lesions were limited to the facial treatment area excluding the eyes, the lips, and angles of the nose (i.e., the lines around the nostrils and under the nostrils) and all mucus membranes.
Interventions
- DRUG Vehicle foam
- DRUG Tazarotene (Fabior™)
- DRUG Tazarotene (Actavis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 893 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
What the finished NCT02267746 record still lists
NCT02267746 is an interventional study that assigns participants to a tested intervention. The registered 893 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 3 interventions - of which Vehicle foam is the first listed.
NCT02267746 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02267746 about?
NCT02267746 is a clinical study titled "A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris". The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
What is the current status of trial NCT02267746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 893 participants. The study started on 2014-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02267746?
The interventions under investigation include: Vehicle foam (DRUG), Tazarotene (Fabior™) (DRUG), Tazarotene (Actavis) (DRUG).
Who is sponsoring clinical trial NCT02267746?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02267746's enrollment target sits among peer trials
893 363rd of 2000 higher than 1,638 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia